Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific ...

Tuesday, November 18, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft ...

Blood-thinning drugs that doctors often prescribe interchangeably after procedures to reopen narrowed heart arteries don’t ...

A representative for pharmaceutical company Eli Lilly says that the man is now "receiving the best medical care." ...

The drugmaker said Monday that it has started selling higher doses of the injectable obesity treatment for $349 a month to ...

Neurona Therapeutics, a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for disorders of the nervous system, today announced the appointment of Eduardo ...

Get the latest on S&P 500 healthcare stocks, top gainers/losers, sector news, major deals, and policy moves impacting investments.

Eli Lilly (LLY) drops CVS Health's (CVS) drug plan after the health insurer limited access to its obesity drug, Zepbound in favor of Novo's (NVO) Wegovy. Read more here.

To build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients ...

A medical executive collapsed during a White House press conference announcing a deal to lower weight loss drug prices. White ...